- Conditions
- Chronic Kidney Disease
- Interventions
- Lorundrostat 25mg+SGLT2i QD, Washout, Placebo+SGLT2i QD, Placebo QD + SGLT2i QD, Washout, Lorundrostat 25mg+SGLT2i QD
- Drug
- Lead sponsor
- Mineralys Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 44
- States / cities
- Glendale, Arizona • Phoenix, Arizona • Chula Vista, California + 39 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 745–768
of 6,846
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hepatitis
- Interventions
- Larsucosterol, Placebo
- Drug
- Lead sponsor
- Bausch Health Americas, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 92
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 65 more
- Conditions
- Migraine With or Without Aura
- Interventions
- Lasmiditan 50 mg, Lasmiditan 100 mg, Lasmiditan 200 mg, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,005 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 95
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 80 more
- Conditions
- Mantle-Cell Lymphoma
- Interventions
- Ibrutinib, Venetoclax, Placebo Oral tablet to match Venetoclax
- Drug
- Lead sponsor
- Pharmacyclics LLC.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 366 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 14
- States / cities
- Tucson, Arizona • Duarte, California • Los Angeles, California + 10 more
- Conditions
- Lymphoma
- Interventions
- carmustine, cyclophosphamide, etoposide, mesna, peripheral blood stem cell transplantation
- Drug · Procedure
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2007
- U.S. locations
- 206
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 151 more
- Conditions
- Obstructive Sleep Apnea, Hypertension
- Interventions
- Lorundrostat, Placebo
- Drug
- Lead sponsor
- Mineralys Therapeutics Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 27
- States / cities
- Tuscaloosa, Alabama • Chandler, Arizona • Little Rock, Arkansas + 24 more
- Conditions
- Childhood Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, Clear Cell Sarcoma of the Kidney, Papillary Renal Cell Carcinoma, Rhabdoid Tumor of the Kidney, Stage I Renal Cell Cancer, Stage I Renal Wilms Tumor, Stage II Renal Cell Cancer, Stage II Renal Wilms Tumor, Stage III Renal Cell Cancer, Stage III Renal Wilms Tumor, Stage IV Renal Cell Cancer, Stage IV Renal Wilms Tumor
- Interventions
- Doxorubicin Hydrochloride, Irinotecan Hydrochloride, Conventional Surgery, Cyclophosphamide, Etoposide, Carboplatin, Dactinomycin, Vincristine Sulfate, Radiation Therapy, Laboratory Biomarker Analysis
- Drug · Procedure · Biological + 2 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 29 Years
- Enrollment
- 291 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 161
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 127 more
- Conditions
- Fibromyalgia
- Interventions
- placebo, pregabalin (Lyrica)
- Drug
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 107 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 30
- States / cities
- Los Angeles, California • Santa Ana, California • Delray Beach, Florida + 18 more
- Conditions
- Schizophrenia
- Interventions
- TV-46000, Placebo
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 13 Years to 65 Years
- Enrollment
- 544 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 73
- States / cities
- Little Rock, Arkansas • Rogers, Arkansas • Anaheim, California + 58 more
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Iza-bren, Osimertinib, Pemetrexed, Carboplatin, Cisplatin
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 850 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 37
- States / cities
- Beverly Hills, California • Fullerton, California • La Jolla, California + 32 more
- Conditions
- Menopause
- Interventions
- Estradiol, Progesterone, Placebo
- Drug
- Lead sponsor
- TherapeuticsMD
- Industry
- Eligibility
- 40 Years to 65 Years · Female only
- Enrollment
- 1,845 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 119
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 99 more
- Conditions
- Type 2 Diabetes
- Interventions
- Cagrilintide, Semaglutide, Placebo
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 189 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 21
- States / cities
- Huntington Park, California • Northridge, California • Santa Ana, California + 18 more
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor
- Interventions
- JZP898, Pembrolizumab
- Drug
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 177 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 10
- States / cities
- Encinitas, California • Fresno, California • Denver, Colorado + 7 more
- Conditions
- Hodgkin Lymphoma
- Interventions
- brentuximab vedotin, doxorubicin, bleomycin, vinblastine, dacarbazine
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,334 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2026
- U.S. locations
- 83
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Tucson, Arizona + 80 more
- Conditions
- Neuroblastoma Recurrent
- Interventions
- DFMO, Bortezomib
- Drug
- Lead sponsor
- Giselle Sholler
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2024
- U.S. locations
- 6
- States / cities
- Little Rock, Arkansas • Hartford, Connecticut • Orlando, Florida + 3 more
- Conditions
- Melanoma
- Interventions
- Encorafenib, Binimetinib, Pembrolizumab
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 257 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 27
- States / cities
- Orlando, Florida • Fairway, Kansas • Overland Park, Kansas + 16 more
- Conditions
- Chronic Idiopathic Constipation
- Interventions
- Plecanatide
- Drug
- Lead sponsor
- Bausch Health Americas, Inc.
- Industry
- Eligibility
- 18 Years to 81 Years
- Enrollment
- 2,370 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 211
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Gulf Shores, Alabama + 160 more
- Conditions
- Osteoarthritis, Knee
- Interventions
- LY2951742, Placebo- oral, Placebo - SC, Celecoxib
- Drug · Other
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 40 Years to 75 Years
- Enrollment
- 268 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 38
- States / cities
- Birmingham, Alabama • Anaheim, California • San Diego, California + 31 more
- Conditions
- Diabetic Retinopathy
- Interventions
- BI 764524, Sham control of BI 764524
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 13
- States / cities
- Dothan, Alabama • Beverly Hills, California • Palo Alto, California + 10 more
- Conditions
- Benign Prostatic Hypertrophy
- Interventions
- Cetrorelix Pamoate
- Drug
- Lead sponsor
- AEterna Zentaris
- Industry
- Eligibility
- 50 Years and older · Male only
- Enrollment
- 528 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 56
- States / cities
- Homewood, Alabama • Huntsville, Alabama • Laguna Hills, California + 49 more
- Conditions
- Depressive Disorder, Major
- Interventions
- Seltorexant, Placebo, Selective Serotonin Reuptake Inhibitor (SSRI)/Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 74 Years
- Enrollment
- 752 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 84
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Tucson, Arizona + 65 more
- Conditions
- Neovascular Age-Related Macular Degeneration (NVAMD), Branch Retinal Vein Occlusion (BRVO)
- Interventions
- Remigromig, Aflibercept 2.0 mg
- Drug
- Lead sponsor
- EyeBiotech Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 55
- States / cities
- Scottsdale, Arizona • Glendale, California • Modesto, California + 34 more
- Conditions
- Solid Tumors Harboring NTRK Fusion
- Interventions
- Larotrectinib (Vitrakvi, BAY2757556)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- Up to 21 Years
- Enrollment
- 154 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2026
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Palo Alto, California • Orlando, Florida + 7 more
- Conditions
- Hemophilia A
- Interventions
- rAHF-PFM
- Drug
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- Male only
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 37
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Duarte, California + 30 more